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Development
All CNS glial cell types (except microglia) differentiate from a neural stem cell (NSC) pool during embryogenesis—around 16–18 weeks in human gestation (E17 in rodents)—
with the peak of astrogliogenesis occurring during late prenatal/early postnatal development (P1 to P10 in rodents). Astrocyte fate specifi cation is still poorly understood, though 
recent studies indicate that JAK/STAT, BMP/SMAD, Notch, and nuclear factor IA (NFIA) may all play roles (Rowitch and Kriegstein, 2010). Astrocytes undergo an intense process 
of maturation following differentiation from the common NSC pool, after which astrocyte-specifi c morphology and functions are acquired. Evolutionarily, both number and size/
complexity of astrocytes increase such that the invertebrate CNS contains only 20% astrocytes and these are comparatively small in size, whereas human astrocytes are much 
larger with multi-branched processes that constitute up to 50% of CNS cells (Khakh and Sofroniew, 2015).
Heterogeneity
Morphologically, astrocytes are multi-process-bearing stellate cells. Several morphologically distinguishable types of astrocyte exist, including protoplasmic (gray matter) 
and fi brous (white matter). Each subclass exhibits a degree of molecular heterogeneity that is only now beginning to be investigated. Expression of GFAP is commonly used as a 
specifi c marker for astrocyte identifi cation, although in vivo, it is primarily expressed by white matter astrocytes. The folate dehydrogenase enzyme Aldh1l1 is a recently identifi ed 
marker for both white and gray matter astrocytes.
Protoplasmic: the most prevalent type of astrocytes extend thick, short primary branches originating from the soma that divide profusely into secondary branchlets, tertiary 
leafl ets and fi nally characteristic endfeet, which, in addition to encasing blood vessels, are capable of ensheathing several thousand synapses (Khakh and Sofroniew, 2015; 
Bushong et al., 2002). Uninterrupted connected endfeet form a limiting membrane on the pia mater inner surface. Perivascular endfeet, along with endothelial cells of cerebral 
blood vasculature, form the glia limitans, a space between blood vessels and astrocytes involved in “glymphatic” drainage (Iliff et al., 2012). This provides for para-arterial infl ux 
of nutrients to neurons and para-venous clearance of toxic metabolites from the CNS.
Fibrous: have longer, thinner processes that remain mostly unbranched. Terminal processes still form endfeet, which envelop nodes of Ranvier (and contact blood vessels). 
Fibrous astrocytes are most notably involved in repair of damaged tissue (especially in spinal cord), a process resulting in scar formation (Sofroniew and Vinters, 2010).
Radial: specialized astrocytes that are the fi rst cells to develop from NSCs during very early embryogenesis and form a scaffold to assist neuron migration. After maturation, 
they transform into stellate astrocytes, although radial glial cells remain in the retina (Müller glia) and cerebellum (Bergmann glia).
Function
Originally thought to primarily mediate ionic homeostasis and provide structural support and passive maintenance for neurons (as a barrier against spread of transmitters from 
synapses, preventing activity of one neuron from affecting neighboring neurons), far more active roles are now known to be played by astrocytes.
Neurotrophic support: instrumental in promoting neuronal survival through release of as-yet-unidentifi ed neurotrophic factors that are required in vitro and in vivo for neuronal viability.
Synaptogenesis, maturation, and maintenance: astrocytes are critical for formation and maturation of inhibitory and excitatory synapses via release of a range of molecules, 
including cholesterol, glypicans (GPC4/6), hevin (SPARCL1), thrombospondins (including THBS1/2; see Clarke and Barres, 2013) that can control both pre- and postsynaptic func-
tion. Some factors produce synapses that are immature and functionally silent; however, phases of synapse maturation are conferred via secretion of glypicans and other signals 
from astrocytes later in development that recruit AMPA receptors to the synaptic surface.
Synaptic pruning: active elimination of synapses in mammalian CNS via MERTK- and MEGF10-dependent pathways (Chung et al., 2013) and Drosophila via DRAPER (Tasdemir-
Yilmaz and Freeman, 2014)—these phagocytic pathways differ from the complement-dependent mechanisms of microglia.
Inter-astrocytic communication: Ca2+ waves slowly propagate through gap junctions connecting adjacent astrocyte cytoplasmic compartments. This microdomain signaling takes 
tens of seconds (compared to neuronal millisecond action potentials) and is spontaneous (whole CNS) or mediated by neuronal action potentials (hippocampal CA1/dentate gyrus; 
Khakh and Sofroniew, 2015). Astrocytic calcium waves help to control blood fl ow by inducing release of prostanoids, arachidonic acid, and other molecules that signal vasodilation 
or vasoconstriction depending on metabolic context, coupling blood fl ow to neuronal energy demand (Attwell et al., 2010).
Additional neuronal support: bridging the gap between CNS vasculature and neurons, astrocytes take up, metabolize, and secrete a range of molecules vital for neuron health. 
For instance, astrocytes exhibit high glycolytic rates in vivo producing lactate, which is shuttled to neurons for energy. Neurotransmitters such as glutamate and GABA are taken up 
by astrocytes, thereby terminating their action (Attwell et al., 2010). Similarly, water is taken up by the AQP4 transporter and K+ ions released by neuronal activity fl ow into astrocytes.
Injury and Disease
Astrocyte dysfunction, termed “reactive astrogliosis,” is a common response to all CNS injuries/diseases encompassing a spectrum of changes ranging from hypertrophy to 
chronic scar-forming proliferating and migrating astrocytes (Sofroniew and Vinters, 2010). It has recently been proposed, based on gene profi ling studies, that there are at least 
two types of reactive astrocytes, depending on the inducing CNS injury, called A1 and A2, which may be harmful or benefi cial in neuroinfl ammation and ischemia, respectively 
(Zamanian et al., 2012). Clearly, A2 reactive astrocytes promote healing after ischemic injury (Sofroniew and Vinters, 2010). Potential deleterious functions exhibited by A1s could 
fall into two general categories: loss of function, where astrocytes fail to perform normal functions, or gain of function, where they begin to present new, possibly deleterious, 
functions not seen in resting astrocytes. Neuroinfl ammatory (A1) reactive astrocytes exhibit a gene profi le phenotype suggesting that they are detrimental (upregulating many 
complement cascade components needed to drive synapse destruction; Zamanian et al., 2012). Astrocyte reactivity is also seen in chronic neurological disease associated with 
aging, such as Huntington’s, Parkinson’s, and Alzheimer’s diseases and in ALS. A better understanding of astrocyte activation in disease is paramount, as astrocyte dysfunction 
has been associated with neurodegeneration (Khakh and Sofroniew, 2015).
Conclusions
Astrocytes display a range of functional attributes indispensable for the normal development and function of the CNS. A better understanding of the remarkable heterogeneity 
that astrocytes display in morphology and function—and how these become altered due injury or disease—may therefore offer novel insights into treatment of CNS disorders.
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